154045-69-9

Upstream product

• 107-30-2 chloromethyl methyl ether 
• 86-51-1 2,3-dimethyoxybenzaldehyde 
• 5150-42-5 2,3-dimethoxyphenol 

Downstream Products

• 154045-68-8 N,N-diethyl-2-methoxy-6-(methoxymethoxy)benzamide 
• 145645-17-6 methyl 2-methoxy-6-(methoxymethoxy)benzoate 
• 227473-81-6 3,4-dimethoxy-2-(methoxymethoxy)phenylboronic acid 
• 132594-07-1 3'-hydroxy-7,8,4-trimethoxyflavonol 
• 65548-55-2 3',4',7,8-(OMe)4-flavon 
• 109979-37-5 7,8,4'-trimethoxy-3'-(methoxymethoxy)flavonol 
• 57499-09-9 2'-hydroxy-3',4'-dimethoxy-4-(methoxymethoxy)chalcone 
• 110048-37-8 3',4',7,8-tetramethoxyflavanone 
• 109469-85-4 3'-hydroxy-7,8,4'-trimethoxyflavanone 

Relevant academic research and scientific papers

Convenient synthesis and physiological activities of flavonoids in Coreopsis lanceolata L. petals and their related compounds

Chalcones, flavanones, and flavonols, including 8-methoxybutin isolated from Coreopsis lanceolata L. petals, were successfully synthesized with total yields of 2–59% from O-methylpyrogallols using the Horner–Wadsworth–Emmons reaction as a key reaction. Au

Co-administration of dopamine-receptor binding compounds

Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D1 receptor agonist, and administering to the patient an effective amount of a dopamine D2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D1 receptor agonist and a dopamine D2 receptor antagonist are also described. The D1 dopamine receptor agonist and the D2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS

Methods for treating a patient having pulmonary edema are described. The methods include administering to the lung endobronchial space of the airways of the patient an effective amount of a dopamine D1 receptor agonist. Dopamine D1 receptor agonists, including hexahydrobenzophenanthridine, hexahydrothienophenanthridine, phenylbenzodiazepine, chromenoisoquinoline, naphthoisoquinoline dopamine receptor agonists, and their pharmaceutically acceptable salts, formulated as aerosols and dry powders are also described.

Synthesis of the CD-ring of the anticancer agent streptonigrin: studies of aryl-aryl coupling methodologies

A series of functionalized 4-bromopyridines, representing the C-ring of the anticancer agent streptonigrin have been prepared and their abilities to undergo Pd-catalyzed cross-coupling with streptonigrin D-ring siloxanes were evaluated. The coupling reaction was generally tolerant to the preparation of hindered CD biaryls; however, the electronic effects of both partners play a pivotal role in the success of the coupling process. Analogs of the CD biaryl were prepared by coupling of aryl siloxane derivatives (D-ring component) with highly functionalized 4-bromopyridines (C-ring); however, the CD biaryl of the natural product could not be prepared in high yield by siloxane coupling due to the facile formation of reduced pyridine under the coupling conditions. Alternatively, the fully functionalized CD biaryl of streptonigrin was prepared using a Suzuki coupling of appropriately functionalized C-ring bromide and D-ring aryl boronic acid. The described approach is highly convergent and readily amenable to the synthesis of analogs.

8,9-Dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms

The synthesis and preliminary pharmacological evaluation of 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (5, now named dinoxyline) is described. This molecule was designed as a potential bioisostere that would conserve the essential elements of our β-phenyldopamine D 1 pharmacophore (i.e., position and orientation of the nitrogen, hydroxyls, and phenyl rings). Previously, we have rigidified these elements using alkyl bridges, as exemplified in the dopamine D1 full agonist molecules dihydrexidine (1) and dinapsoline (2). This approach has been modified and we now show that it is possible to tether these elements using an ether linkage. Preliminary pharmacology has revealed that 5 is a potent full D1 agonist (K0.5 50=30 nM), but also has high affinity for brain D2-like and cloned D2 and D3 receptors. Interestingly, whereas 1 and 2 and their analogues have only moderate affinity for the human D4 receptor, 5 also has high affinity for this isoform. Moreover, although N-alkylation of 1 and 2 increases D2 affinity, the N-allyl (15) and N-n-propyl (17) derivatives of 5 had decreased D2 affinity. Therefore, 5 may be engaging different amino acid residues than do 1 and 2 when they bind to the D2 receptor. This is the first example of a ligand with high affinity at all dopamine receptors, yet with functional characteristics similar to dopamine. These rigid ligands also will be useful tools to determine specific residues of the receptor transmembrane domains that are critical for agonist ligand selectivity for the D4 receptor.

Siloxane-Based Cross-Coupling of Bromopyridine Derivatives: Studies for the Synthesis of Streptonigrin and Lavendamycin

(Equation Presented) Highly functionalized 4-bromopyridines were prepared and found to undergo fluoride-promoted, Pd-catalyzed cross-coupling with aryltrialkoxy-silanes to give sterically demanding biaryls. The 3-nitro-4-bromopyridine derivative coupled i

Chromeno[4,3,2-DE]isoquinolines as potent dopamine receptor ligands

Novel dopamine receptor ligands of the formula: pharmaceutical formulations of such compounds, and a method using such compounds for treating a patient suffering from dopamine-related dysfunction of the central or peripheral nervous system, are described.

Cross coupling strategies towards the synthesis of the streptonigrin CD moiety

An efficient route to an appropriate model of the streptonigrin 4- phenylpyridine CD moiety is reported. 4-Chloro-3-nitropyridine was found to be the key precursor and its reactivity in cross coupling reactions was further investigated.

Design of photoaffinity reagents for labeling the auxin receptor in maize

In order to isolate the auxin receptor, we have successfully synthesized two analogues of benzoxazolinones with a trifluoromethyldiazirine group as a photoaffinity probe. These compounds inhibited the auxin-induced growth of etiolated Avena coleoptile segments. Photolyses of these compounds in methanol gave intermolecular O-H insertion products in moderate yields, respectively.